Observational studyEpidemiology and infection2025
Protection from second booster vaccines and natural immunity against SARS-CoV-2 infections, 2022-2023.
Observational study in Epidemiology and infection, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
We estimated the vaccine effectiveness (VE) of second monovalent and bivalent booster vaccines containing Omicron BA.1 or BA.4/BA.5 and the protection conferred by natural immunity against SARS-CoV-2 infection in Luxembourg. We conducted a test-negative case-control study among residents aged 60 years or older by integrating national socio-demographic, COVID-19 vaccination, and testing data, achieving full population coverage. Using conditional logistic regression, we estimated absolute and relative VE of monovalent and bivalent boosters and natural immunity from prior infection. Our analysis included 5,390 test-positive cases and 11,048 test-negative controls matched by week of testing between September 2022 and April 2023. Absolute VE for monovalent and bivalent boosters decreased from 64.8% and 66.6% in the first month to 1.5% and 16.5% after 5-6 months, respectively. The bivalent was superior to the monovalent booster only in individuals without natural immunity (relative VE 25.7%, 95% confidence interval 11.4%; 37.7%). Natural immunity lasted longer than vaccine-induced immunity with 80.7% protected at 4-8 months and 44.9% at 15-25 months post-infection. Both second booster vaccines provided temporary protection against SARS-CoV-2 infection; bivalent boosters offered a slight benefit over monovalent boosters. Natural immunity appears to confer longer-lasting protection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.